TRMU

Across TCGA pan-cancer cohorts, TRMU mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TRMU data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher TRMU mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TRMU expression acts as an unfavorable survival marker, although some lineages such as COAD and UCEC show a favorable association.

COAD, LUAD, and LSCC are the cancer types where TRMU mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	III,IV	1.000	0.859	.030	6	view →
LUAD	OS	Median	All	0.780	0.901	.020	6	view →
LSCC	OS	Quartile	III,IV	0.591	0.918	.038	6	view →
UCEC	OS	Quartile	II,III,IV	1.000	0.520	.043	4	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →
CCRCC	DFS	Tertile	III,IV	0.447	0.810	.043	2	view →
GBM	OS	Median	All	0.447	0.606	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TRMU–COAD (DFS)

Open the COAD breakdown →